pdufa.bio

ICOTYDE (icotrokinra)

Updated ยทnext FDA decision on the calendar

ICOTYDE (icotrokinra) The FDA approved it on Mar 18, 2026. 2 FDA decisions on record below. Every date links its source.

JNJ catalyst hub · PTGX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Mar 18, 2026 ✓ ApprovedJNJPDUFA · Mar 18, 2026 ✓ ApprovedPTGX

Questions

When is ICOTYDE (icotrokinra)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for ICOTYDE (icotrokinra); 2 FDA decisions are on record below.

What happened at ICOTYDE (icotrokinra)'s most recent FDA decision?

On Mar 18, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has ICOTYDE (icotrokinra) been approved by the FDA?

Yes. The FDA approved an application for ICOTYDE (icotrokinra) on Mar 18, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.